Certara Products - Phoenix Archives | Certara

Blog

The Reference-scaled Average Bioequivalence (RSABE) Approach

We examine the Reference-scaled Average Bioequivalence (RSABE) approach for generic drug development and how it…

CertaraJuly 1, 2025

Announcement

Certara Enhances Integral Data Repository with Powerful REST API Capabilities in Version 25.4.1

Radnor, PA – June 20, 2025 - Certara, Inc. (Nasdaq: CERT), a global leader in…

Danielle PillsburyJune 20, 2025

Announcement

Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power

June 16, 2025 RADNOR, PA – June 16, 2025 – Certara, Inc. (Nasdaq: CERT), a…

CertaraJune 16, 2025

Webinar

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

Danielle PillsburyJune 11, 2025

Publication

Assessment of the Effects of Fruquintinib on Cardiac Safety in Patients with Metastatic Colorectal Cancer

The study, published in the Journal of Clinical Pharmacology, evaluates the cardiac safety of fruquintinib,…

CertaraJune 8, 2025

On-Demand Webinar

On-Demand Webinar: Streamlining Population PK Modeling with Phoenix NLME and Pirana

Phoenix NLME offers unparalleled flexibility and power for PK/PD analyses, meeting all scientific and technical…

Danielle PillsburyJune 5, 2025

Webinar

Transform Your PK/PD Workflow with AI and the Cloud

Danielle PillsburyJune 5, 2025

Webinar

Accelerate IVIVC Modeling: How Formulation Scientists Can Save Time and Reduce Clinical Study Burden

CertaraJune 5, 2025

On-Demand Webinar

Pharmacokinetic Modeling of Neutralizing ADA Effects in Translational Development

CertaraMay 21, 2025

Blog Knowledge Base

Extrapolating AUC to Infinity

AUC calculations are simple but nuanced. In this blog, we look at how to extrapolate…

CertaraMay 15, 2025

© 2025 Certara. All Rights Reserved. | Privacy policy